Abstract
Retrotransposable elements (RTEs) are deleterious at multiple levels, and failure of host surveillance systems can thus have negative consequences. However, the contribution of RTE activity to aging and age-associated diseases is not known. Here we show that during cellular senescence LINE-1 elements (L1s) become transcriptionally derepressed and activate a type-I interferon (IFN-I) response. The IFN-I response is a novel phenotype of late senescence and contributes to the maintenance of the senescence associated secretory phenotype (SASP). The IFN-I response is triggered by cytoplasmic L1 cDNA, and is antagonized by nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit the L1 reverse transcriptase (RT). Treatment of aged mice with the NRTI lamivudine downregulated IFN-I activation and age-associated inflammation in several tissues. We propose that RTE activation is an important component of sterile inflammation that is a hallmark of aging, and that L1 RT is a relevant target for the treatment of age-associated disorders.
RTE activity can promote aberrant transcription, alternative splicing, insertional mutagenesis, DNA damage and genome instability1. RTE-derived sequences comprise up to two thirds of the human genome2, although the great majority were active millions of years ago and are no longer intact. The only human RTE capable of autonomous retrotransposition is the long-interspersed element-1 (LINE-1, or L1). However, germline activity of L1 is a major source of human structural polymorphisms3. Increasing evidence points to RTE activation in some cancers, in the adult brain, and during aging4–7. Cellular defenses include heterochromatinization of the elements, small RNA pathways that target the transcripts, and anti-viral innate immunity mechanisms8. Somatic activation of RTEs with age is conserved in yeast and Drosophila and reducing RTE activity has beneficial effects8.
Activation of L1 and interferon in cellular senescence
We show here that L1 transcription is activated exponentially during replicative senescence (RS) of human fibroblasts, increasing 4–5-fold by 16 weeks after cessation of proliferation, which we refer to as late senescence (Fig. 1a, Extended Data Fig. 1a-e). Multiple RT-qPCR primers were designed to detect evolutionarily recent L1 elements (L1HS-L1PA5; Fig. 1b, Extended Data Fig. 1h). Levels of L1 polyA+ RNA increased 4–5-fold in late senescent cells (RS) in the sense but not antisense direction throughout the entire element (Fig. 1c). We Sanger sequenced long-range RT-PCR amplicons (Fig. 1b) to identify 224 elements dispersed throughout the genome; one third (75, 33.5%) were L1HS, of which 19 (25.3%, 8.5% of total) were intact (i.e. are annotated to be free of ORF-inactivating mutations; Extended Data Fig. 1f, g). We also performed 5’RACE with the same primers and found that the majority of L1 transcripts upregulated in senescent cells initiated within or near the 5’UTR (Extended Data Fig. 2).
L1 elements can stimulate an IFN-I response9. We found that interferons IFN-α and IFN-β1 were induced to high levels in late senescent cells. (Fig. 1d, Extended Data Fig. 1i). Cellular senescence proceeds through an early DNA damage response phase followed by the SASP response10. We document here a third and even later phase, characterized by the upregulation of L1 and an IFN-I response (Fig. 1e), which has not been previously noted, probably because most studies have focused on earlier times. Whole transcriptome RNA-seq analysis confirmed that the SASP and IFN-I responses are temporally distinct (Extended Data Fig. 3). The late phase of L1 activation and IFN-I induction was also observed in oncogene-induced senescence (OIS) and stress-induced premature senescence (SIPS) (Fig. 1e, Extended Data Fig. 1j, k).
Mechanisms of L1 activation
To explore how surveillance fails during senescence we examined three factors: TREX1, RB1 and FOXA1. TREX1 is a 3’ exonuclease that degrades foreign invading DNAs and its loss has been associated with the accumulation of cytoplasmic L1 cDNA11. We found that the expression of TREX1 was significantly decreased in senescent cells (Extended Data Fig. 4a). RB1 has been shown to bind to repetitive elements, including L1s, and promote their heterochromatinization12. We found that the expression of RB1 declined strongly in senescent cells (RS; Fig. 2a) while that of other RB family members (RBL1, RBL2) did not change (Extended Data Fig. 4b). RB1 enrichment in the 5’UTR of L1 elements was evident in proliferating cells, decreased in early senescence and became undetectable at later times (Fig. 2a). This coincided with a decrease of H3K9me3 and H3K27me3 marks in these regions (Extended Data Fig. 4c).
To identify novel factors that interact with the L1 5’UTR we examined the ENCODE ChIP-seq database and found that the pioneering transcription factor FOXA1 binds to this region in several cell lines (Extended Data Fig. 4d). FOXA1 is upregulated in senescent cells13 and bound to the central region of the L1 5’UTR (Fig. 2b). Using transcriptional reporters we found that deletion of the FOXA1 binding site decreased both sense and antisense transcription from the L1 5’ UTR14 (Extended Data Fig. 4e). Hence, the observed misregulation of these three factors in senescent cells could promote the activation of L1 by three additive mechanisms: loss of RB1 by relieving heterochromatin repression, gain of FOXA1 by activating the L1 promoter, and loss of TREX1 by compromising the removal of L1 cDNA.
We thus tested the effects of manipulating RB1, FOXA1 or TREX1 expression in fully senescent cells using lentiviral vectors (Extended Data Fig. 5a, b). Ectopic expression of RB1 suppressed the elevated expression of L1, IFN-α and IFN-β1 in senescent cells, while its knockdown further enhanced their expression (Fig. 2d). RB1 overexpression also restored its occupancy of the L1 5’UTR (Fig. 2c). Conversely, knockdown of FOXA1 reduced its binding to the L1 5’UTR (Extended Data Fig. 4f) and decreased the expression of L1, IFN-α and IFN-β1, while overexpression of FOXA1 increased L1, IFN-α and IFN-β1 levels (Fig. 2e). Congruent results were also obtained by manipulating TREX1 (Fig. 2g). Hence, each of these factors had a tangible effect on regulating L1 and the IFN-I response in senescent cells.
Single or double interventions targeted at these factors elicited only modest changes in L1 and IFN-I expression in growing early passage cells. While some of these effects were statistically significant, they were dwarfed by a triple intervention of RB1 and TREX1 104knockdowns combined with FOXA1 overexpression (3X), which resulted in a massive induction of L1 and IFN-I expression (Fig. 2f, Extended Data Fig. 4g-i and 5c). Hence, in normal healthy cells all three effectors have to be compromised to effectively unleash L1.
Consequences of L1 activation
To assess IFN-I activation by L1 in more detail we examined the expression of 84 genes in this pathway using PCR arrays. We observed a widespread response, with the majority of the genes being upregulated (Fig. 2h, Extended Data Fig. 4j, k): 68% (57/84) were significantly upregulated in senescent cells, and 52% (44/84) were upregulated in 3X cells. These data verify and further extend the RNA-seq transcriptomic analysis (Extended Data Fig. 3).
Some NRTIs developed against HIV have been found to also inhibit L1 RT activity15. We also developed shRNAs against L1, two of which reduced transcript levels by 40–50% and 70–90% in deeply senescent and 3X cells, respectively (Extended Data Fig. 5g). ORF1 protein levels were correspondingly reduced in deeply senescent cells (Extended Data Fig. 5h). Finally, the shRNAs also reduced the retrotransposition of recombinant L1 reporter constructs (Extended Data Fig. 5k).
Cells devoid of TREX1 display cytoplasmic L1 DNA, accumulation of which can be inhibited with NRTIs11. While lack of BrdU incorporation is a canonical feature of senescent cells (Extended Data Fig. 1b), longer term labeling revealed DNA that was predominantly cytoplasmic and highly enriched for L1 sequences (Extended Data Fig. 6a, b). The synthesis of cytoplasmic L1 DNA could be almost completely blocked with the NRTI lamivudine (3TC) or shRNA to L1 (Fig. 3a, c). An antibody to DNA:RNA hybrids detected a cytoplasmic signal in senescent cells that largely colocalized with ORF1 protein and turned into a ssDNA signal following RNase digestion (Extended Data Fig. 6c). Analysis of BrdU-labeled L1 sequences in senescent cells showed them to be localized throughout the L1 element (Extended Data Fig. 6d, e). A relative increase of L1HS sequences in total cellular DNA can also be detected by a qPCR assay6,16. 3TC in the range of 7.5–10 μM completely blocked this increase in senescent cells and also quenched the activity of a L1 retrotransposition reporter (Extended Data Fig. 5d, e).
L1 knockdown with shRNA or treatment of cells with 3TC significantly reduced interferon levels, as well as reducing the IFN-I response more broadly in both late senescent and 3X cells (Fig. 3b, Extended Data Fig. 7a). 3TC in the range of 7.5–10 μM optimally inhibited the IFN-I response, and was the most effective of 4 NRTIs tested (Extended Data Fig. 5f, j). The relative efficacies of the NRTIs are consistent with their ability to inhibit human L1 RT15. 3TC also antagonized the IFN-I response in other forms of senescence, OIS and SIPS (Fig. 3e).
We passaged cells in the continuous presence of 3TC from the proliferative phase into deep senescence. 3TC did not significantly affect the timing of entry into senescence, induction of p21 or p16, or the early SASP response (such as upregulation of IL-β) (Fig. 3f, Extended Data Fig. 7b). However, the magnitude of the later SASP response (such as induction of CCL2, IL-6 and MMP3) was significantly dampened. Treatment with L1 shRNA also reduced the expression levels of IL-6 and MMP3 in late senescent cells (Extended Data Fig. 6f). Hence, while L1 activation and the ensuing IFN-I response are relatively late in onset, they contribute importantly to the mature SASP and proinflammatory phenotype of senescent cells.
3TC did not affect L1 transcript levels (Extended Data Fig. 5i), suggesting that the INF-I response is triggered by L1 cDNA. As this model would predict, knockdown of the cytosolic DNA sensing pathway components cGAS or STING17 inhibited the IFN-I response in both late senescent and 3X cells (Extended Data Fig. 5l and Fig. 7c, d), and also downregulated the SASP response in late senescent cells (Extended Data Fig. 7e).
NRTIs alkyl-modified at the 5’ ribose position cannot be phosphorylated and hence do not inhibit RT enzymes; however, they possess intrinsic anti-inflammatory activity by inhibiting P2X7-mediated events that activate the NLRP3 inflammasome pathway18. Tri-methoxy-3TC (K-9), at 10 μM or 100 μM, did not inhibit the IFN-I response in either late senescent or 3X cells (Extended Data Fig. 7f). Hence, the effect of 3TC on the IFN-I pathway requires RT inhibition. At high concentrations (100 μM) K-9 had some inhibitory activity on markers of inflammation, as reported18 (Extended Data Fig. 7g).
To test the role of interferon signaling in SASP we inactivated the IFN-α/β receptors (IFNAR1 and 2) using CRISPR/Cas9. Effective ablation of IFN-I signaling was achieved in both early passage and deep senescent cells (Extended Data Fig. 5m). In both replicative and SIPS forms of senescence, loss of interferon signaling antagonized late (CCL2, IL-6, MMP3) but not early (IL-1β) SASP markers (Fig. 3d). This further demonstrates that IFN-I signaling contributes to the establishment of a full and mature SASP response in senescent cells.
Activation of L1 in human and mouse tissues
Activation of L1 expression in human cancers has been detected with an ORF1 antibody4. The same reagent showed widespread ORF1 expression in both senescent and 3X cells (Extended Data Fig. 8a, c, f). In skin biopsies of normal aged human individuals, we found that 10.7% of dermal fibroblasts were positive for the senescence marker p16, which is in the range documented in aging primates19 (Extended Data Fig. 8b, d, f, h). Some of the p16 positive dermal fibroblasts were also positive for ORF1 (10.3%). Notably, we never observed ORF1 in the absence of p16 expression. We also detected, at the single cell level, the presence of phosphorylated STAT1, consistent with the presence of interferon signaling in the tissue microenvironment20 (Extended Data Fig. 8b, e, g). Hence, a fraction of senescent cells in normal human individuals display activation of L1, consistent with these events accumulating during the progression of senescence.
We next examined mice and found that L1 mRNA was progressively upregulated with age in several tissues (Extended Data Fig. 10g). The detected L1 RNA sequences were predominantly sense strand, represented throughout the element, and all three active L1 families were detectable (Extended Data Fig. 6g, h). At the protein level, the frequency of L1 Orf1 positive cells increased in tissues with age (Fig. 4a). Regions of Orf1 staining colocalized with senescence-associated β-galactosidase (SA-β-Gal) activity (Fig. 4b). Notably, we found that several IFN-I response genes (Ifn-α, Irf7, Oas1) as well as pro-inflammatory and SASP markers (Il-6, Mmp3, Pai1) were upregulated in tissues of old mice (Fig. 4c, Extended Data Fig. 9). We also observed an increase in L1 expression and IFN-I response genes (Ifn-α, Oas1) in an experimentally induced model of cellular senescence (young animals subjected to sublethal irradiation; Fig. 4d).
We treated old animals (26 months) for two-weeks with 3TC (administered in water at human therapeutic doses) and found a broad and significant downregulation the IFN-I response and alleviation of the SASP pro-inflammatory state (Fig. 4c, for the full dataset see Extended Data Fig. 9 and Supplementary Table 7). Expression of L1 mRNA and p16 was weakly downregulated, but in most cases did not reach statistical significance. K-9 did not affect either the IFN-I or SASP responses. Immunofluorescence analysis of tissue sections confirmed that senescent cells expressed SASP, and Orf1-expressing cells activated IFN-I signaling (Extended Data Fig. 10a-c). Treatment with 3TC significantly reduced both IFN-I and SASP, but not L1 expression or the presence of senescent cells. Hence, NRTIs can be categorized as “senostatic” agents, to contrast them from “senolytic” treatments that remove senescent cells from tissues21,22.
Decreased adipogenesis23 and thermogenesis24 are features of natural aging and both were increased in old animals by 2 weeks of 3TC treatment (Extended Data Fig. 10d-f). Longer term treatments (from 20 to 26 months of age) were effective at opposing several known phenotypes of aging: macrophage infiltration of tissues, a hallmark of chronic inflammation23,25, glomerulosclerosis of the kidney26 and skeletal muscle atrophy27 (Fig. 4e). Macrophage infiltration of white adipose was especially responsive, returning to youthful (5 month) levels with only 2 weeks of 3TC.
The activation of endogenous L1 elements and the ensuing robust activation of an IFN-I response is a novel phenotype of senescent cells, including naturally occurring senescent cells in tissues. This phenotype evolves progressively during the senescence response and appears to be an important, but hitherto unappreciated component of SASP. We show that the expression of three regulators, RB1, FOXA1 and TREX1 changes during senescence, and that these changes are both sufficient and necessary to allow the transcriptional activation of L1s (Fig. 4g). Hence, multiple surveillance mechanisms need to be defeated to unleash L1, which underscores the importance of keeping these elements repressed in somatic cells. We anticipate that future work will uncover additional mechanisms and failure points that can lead to the activation of endogenous RTEs.
Activation of innate immune signaling in response to L1 activation during cellular senescence and aging proceeds through the interferon-stimulatory DNA (ISD) pathway. Cytoplasmic DNA can originate from several sources, such as mtDNA released from stressed mitochondria28 or cytoplasmic chromatin fragments (CCF) released from damaged nuclei29,30. Our results suggest that L1 cDNA is an important inducer of IFN-I in senescent cells. Remarkably, NRTI treatment effectively antagonized not only the IFN-I response but also more broadly reduced age-associated chronic inflammation in multiple tissues. Given
Sterile inflammation, also known as inflammaging, is a hallmark of aging and a contributing factor to many age-related diseases31,32. We propose that activation of L1 elements (and possibly other RTEs in the mouse) promotes inflammaging, and that the L1 RT is a relevant target for the development of drugs to treat age-associated disorders.
METHODS
Cell culture.
Several different strains of normal human fibroblasts were employed in this study. LF1 cells were derived from embryonic lung tissue as described33. These cells have been in continuous use in our laboratory since their isolation in 1996. For this study original samples frozen in 1996 and in continuous storage in our laboratory were recovered and used. IMR-90 and WI-38 cells were obtained from the ATCC. None of these cell lines are listed in the International Cell Line Authentication Committee (ICLAC) database. These normal fibroblast cell lines were cultured using physiological oxygen conditions (92.5% N2, 5% CO2, 2.5% O2), in Ham’s F-10 nutrient mixture (Thermo Scientific) with 15% fetal bovine serum (FBS, Hyclone). Medium was additionally supplemented with L-glutamine (2 mM), penicillin and streptomycin34. Cell cultures were periodically tested for mycoplasma contamination with MycoAlert ® Mycoplasma Detection Kit (Lonza).
To obtain replicatively senescent (RS) cells, LF1 cultures were serially propagated until proliferation ceased. At each passage, after reaching 80% confluence cells were trypsinized and diluted 1:4. Hence each passage is equivalent to approximately 2 population doublings. In early passage cultures the time between passages is constant at approximately 3 days. As cultures approached senescence the time between passages gradually increased. An interval of 2–3 weeks indicated that the culture was in its penultimate passage. At this point, after reaching 80% confluence, the cells were replated at 1:2 dilution, and this time was designated as the last passage (point A in Extended Data Fig. 1a). Some cell growth typically does occur in the next 2–3 weeks, but the cultures do not reach 80%. Under this experimental regimen the majority of the cells in the culture enter senescence within a 3–4 weeks window centered roughly around the time of last passage (grey bar in Extended Data Fig. 1a). At point B (4 weeks) the cultures were trypsinized and replated as described35 to eliminate a small fraction of persisting contact-inhibited cells. Cultures were again replated at point C (8 weeks).
Oncogene-induced senescence (OIS) was elicited by infecting proliferating LF1cells with pLenti CMV RasV12 Neo (gift from Eric Campeau, Addgene plasmid # 22259). Generation of lentiviral particles and the infection procedure are described below. At the end of the infection cells were reseeded at 15–20% confluency and selected with G418 (250 μg/ml) maintained continuously until the end of the experiment Medium was changed every 3 days until the cultures were harvested at the indicated time points. Stress-induced premature senescence (SIPS) was elicited by X-ray irradiation with 20 Gy given at a rate of 87 cGy/min in one fraction using a cesium-137 gamma source (Nordion Gammacell 40). Cells were 15–20% confluent at the time of irradiation. Medium was changed immediately after irradiation, and at 3 day intervals thereafter. 293T cells (Clontech) were used to package lentivirus vectors and were cultured at 37°C in DMEM with 10% FBS under normoxic conditions (air supplemented with 5% CO2).
Nucleoside reverse transcriptase inhibitors.
All NRTIs (lamivudine, 3TC; zidovudine, AZT; abacavir, ABC; emtricitabine, FTC) used in this study were USP grade and obtained from Aurobindo Pharma, Hyderabad, India. For Trizivir (TZV), its constituents (ABC, AZT and 3TC) were combined in the appropriate amounts. Kamuvudine-9 (K-9)36 was provided by Inflammasome Therapeutics.
Mouse husbandry.
Compliance with relevant ethical regulations and all animal procedures were reviewed and approved by the Brown University Institutional Animal Care and Use Committee. C57BL/6J mice of both sexes were obtained from the NIA Aged Rodent Colonies (www.nia.nih.gov/research/dab/aged-rodent-colonies-handbook) at 5 and 18 months of age. The 5 month old animals were sacrificed after a short (1 week) acclimatization period, a variety of tissues were harvested, snap frozen in LN2 and stored at −80°C. The 18 month old animals were housed until they reached a desired age. Mice were housed in a specific pathogen-free AAALAC-certified barrier facility. All procedures were approved by the Brown University IACUC committee. Cages, bedding (Sani-chip hardwood bedding) and food (Purina Lab Chow 5010) were sterilized by autoclaving. Food and water (also sterilized) were provided ad libitum. A light-dark cycle of 12 hours was used (7 AM On, 7 PM Off). Temperature was maintained at 70°F, and humidity at 50%. All animals were observed daily and weighed once per week. In a pilot experiment 3 cohorts of 10 animals each were treated with 3TC dissolved in drinking water (1.5 mg/ml, 2.0 mg/ml, 2.5 mg/ml) continuously from 18 months until sacrifice at 24 months. The fourth (control) cohort was provided with the same water without drug. No significant differences in behavior, weight, or survival were observed between the 4 cohorts during the entire experiment. Once during the experiment (at 20 months of age) the animals were subjected to a single tail bleed of approximately 70 μl. The collected plasma was shipped to the University of North Carolina CFAR Clinical Pharmacology and Analytical Chemistry Core for analysis of 3TC. For the 2 mg/ml cohort the concentration of 3TC in plasma averaged 7.2 μM. This dose of drug was chosen for further experiments to mimic the human HIV therapeutic dose (300 mg per day, 5–8 μM in plasma)37. For the experiments presented in this communication animals were aged in house until they reached 26 months of age. They were then assigned randomly to two cohorts by a technician that was blinded to the appearance or other characteristics of the animals. One cohort was treated for 2 weeks with 2 mg/ml of 3TC in drinking water, and the other (control) cohort with same water without drug, administered in the same manner. At the end of the treatment period all animals were sacrificed and harvested for tissues as described above. All the animals in both cohorts were all included in all subsequent analyses. The experiment was performed on separate occasions with male and female animals. Non-lethal total body irradiation (6 Gy) was performed by the group of Christian Beauséjour as described38 and tissue specimens were shipped to Brown University on dry ice.
PCR.
The ABI ViiA 7 instrument (Applied Biosystems) was used for all experiments. qPCR of DNA was performed using the Taqman system (Applied Biosystems) as described by Coufal et al. (2009)16. 100 pg of purified genomic DNA was used with the indicated primers (Supplementary Table 1). Reverse transcription qPCR (RT-qPCR) of RNA was performed using the SYBR Green system (Applied Biosystems). Polyadenylated RNA was used in all experiments assessing transcription of L1 elements, and total RNA was used for all other genes. Total RNA was harvested using the Trizol reagent (Invitrogen). Poly(A) RNA was isolated from total RNA using the NEBNext Poly(A) mRNA Magnetic Isolation Module (New England Biolabs). 1 μg of total RNA, or 10 ng of poly(A) RNA, were reverse-transcribed into cDNA in 50 μl reactions using the Taqman kit (Applied Biosystems). To assess strand-specific transcription, the random primers in the RT reaction were substituted with a strand-specific primer to the target RNA. 1 μl of each RT reaction was used in subsequent qPCR reactions. GAPDH was used as the normalization control in experiments with human cells. The arithmetic mean of Gapdh and two additional controls (Hsp90 and GusB) was used for normalization of RT-qPCR experiments with murine tissues, with the exception of liver that was normalized to Hsp90 and GusB. For measuring L1 transcription, poly(A) RNA samples were exhaustively digested with RNase-free DNase (Qiagen) prior to the synthesis of cDNA6. Effectiveness of the DNase digestion was assessed using controls that omitted the RT enzyme.
Design of PCR primers.
Primer sets 1 to 5 (Supplementary Table 1, amplicons A to E in Fig. 1b) to human L1 were designed to preferentially amplify elements of the human-specific L1HS and evolutionarily recent primate-specific L1PA(2–6) subfamilies, as follows. First, the consensus sequences of L1HS and L1PA2 through L1PA6 elements were obtained from Repbase (Genetic Information Research Institute, http://www.girinst.org/repbase/update/browse.php). Second, a consensus sequence of these 6 sequences was generated with the Clustal Omega multiple sequence alignment tool (http://www.ebi.ac.uk/Tools/msa/clustalo/)39. Primer design was then done on the overall consensus with Primer3 and BLAST using the NCBI Primer-BLAST tool (http://www.ncbi.nlm.nih.gov/primer-blast/)40. L1 primer pairs were evaluated for their targets using the In-Silico PCR (https://genome.ucsc.edu/cgi-bin/hgPcr) tool against the latest genome assembly (hg38) with a minimum perfect match on 3’ end of each primer equal to 15. Primers to ORF2 (primer set 6, amplicon F in Fig. 1b) were developed by Coufal et al. (2009)16 to preferentially target L1HS. Primers to assess transcription of active murine L1 elements (primer set 37, Supplementary Table 1) were designed on the combined consensus sequence of the L1MdA and L1Tf families obtained from Repbase and validated as described above. L1 primer pairs spanning the full length these elements (primer sets 48–50) were designed using the same strategy. Primer pairs specific to the three active families of murine L1 elements (primer sets 51–53) were designed exploiting polymorphisms in the 5’UTR region. RT-qPCR analysis of L1 transcription was performed on poly(A) purified RNA using the SYBR Green method. For all other (non-L1) genes, whenever possible, primers are separated by at least one intron in the genomic DNA sequence (as indicated in Supplementary Table 1). Primers to the human IFN alpha family were designed against a consensus sequence of all the human IFN alpha gene sequences (IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21) generated with the Clustal Omega multiple sequence alignment tool. All primers against murine targets were designed as described above and are listed in Supplementary Table 1. Sequences of primers corresponding to a consensus of all the murine IFN alpha genes, as well as to the IFNB1 gene, were obtained from the publication by Gautier et al.41. For quantifying relative L1 genomic copy number (human cells) we used the TaqMan multiplex method developed by Coufal et al. (2009)16. These primers are listed as set #6 and set #7 (with their corresponding VIC and 6FAM probes) in Supplementary Table 1.
Chromatin Immunoprecipitation.
All ChIP experiments were performed using the Chromatrap spin column ChIP kit (Porvair). Briefly, 2×106 cells were crosslinked in their culture dishes with 1% formaldehyde (10 min., room temperature), quenched with glycine, washed twice with ice-cold PBS (containing protease inhibitors), and finally scraped into a microfuge tube. Cell pellets were resuspended in 0.4 ml of hypotonic buffer and incubated for 10 min. on ice. Nuclei were spun down, resuspended in 0.3 ml lysis buffer, and sonicated using a Bioruptor UCD-200 instrument (Diagenode) set to pulse on high (30 sec. followed by 30 sec. rest) for a total time of 10 min. The extracts were centrifuged in a microfuge (top speed, 5 min., 4°C) to remove debris, the supernatants were transferred to new tubes, and stored at −80°C. An amount of extract containing 2 μg of DNA was combined with 4 μg of antibody and loaded on a Chromatrap solid phase Protein A matrix. Immunocomplexes were allowed to form overnight at 4˚C with mild agitation, following which the samples were washed and eluted according to the manufacturer’s protocol. Rabbit IgG and 1% input were used as controls. 1 μl of immunoprecipitated DNA was used in each qPCR reaction.
BrdU pull-down.
To obtain quiescent cells, proliferating cells were grown to 50% confluence, serum supplementation of the medium was changed to 0.1% FBS, and incubation was continued until harvest. Quiescent and senescent cells were continuously labeled for two weeks with BrdU (BrdU Labeling Reagent, Thermo Fisher) according to the manufacturer’s protocol for labeling of culture cells. Cell were harvested and counted: 5×105 cells were processed per condition. Genomic DNA was purified via Phenol:Chloroform extraction, RNase A treated and subsequently sheared using a Bioruptor UCD-200 instrument (pulse on Low, 30 seconds on and 30 seconds off, 10 minutes total). DNA tubes were incubated in a heat block (100°C) for exactly one minute and then flash frozen in liquid nitrogen. Tubes were let thaw at room temperature and 1 μg of purified anti-BrdU antibody (BD Pharmingen, Cat. # 555627) was added per tube together with magnetic protein A/G beads and ChIP Dilution Buffer. Immuno-slurries were incubated overnight at 4°C with constant rotation. Immuno-captured BrdU labeled DNA was purified according to the Magna ChIP™ A/G Chromatin Immunoprecipitation Kit (Millipore Sigma). Unbound DNA was kept as input. 1 μl of immunoprecipitated DNA was used in each qPCR reaction. Alternatively, to enrich for single-stranded BrdU-labeled DNA the heat-mediated denaturation was omitted and samples were processed for BrdU pull-down as above. The DNA second strand was then generated by adding a mixture of random primers (Thermo Fisher), second strand synthesis reaction buffer, dNTPs and DNA Pol I (New England Biolabs). The reaction was incubated for 4 hrs. at 16˚C and subsequently purified by phenol-chloroform extraction. Following the second strand synthesis, the dsDNA was end-repaired with the End-It DNA End-Repair Kit (Epicenter, Cat. #ER0720). Blunt-ended fragments were cloned using the Zero Blunt TOPO PCR Cloning Kit (Thermo Fisher), and then used to transform One Shot TOP10 chemically competent E. coli (Thermo Fisher, Cat. # C404010). Individual colonies were picked and subjected to Sanger sequencing using a T7 promoter primer at Beckman Coulter Genomics.
RNA-seq.
Total RNA from early passage, early and deep senescent cells (Extended Data Fig. 1a) was extracted as described above. The total RNA was processed with the Illumina TruSeq Stranded Total RNA Ribo-Zero kit and subjected to Illumina HiSeq2500 2×125bp paired end sequencing using v4 chemistry at Beckman Coulter Genomics Inc. Over 70 million reads were obtained for each sample. The RNA-seq experiment was performed in three biological replicates.
Raw RNA-sequencing reads were aligned to the GrCh38 build of the human genome using HiSat242. Counts mapping to the genome were determined using featureCounts43. Counts were then normalized using the trimmed mean of M-values (TMM) method in EdgeR44. EdgeR was additionally used to derive differential expression from the normalized data set. Differential expression data were then ranked by log2 fold change and input into the GenePattern interface for GSEA Preranked, using 1000 permutations, to determine enrichment for KEGG pathways, SASP, and the interferon response45,46. The outputs were then corrected for multiple comparisons by adjusting the nominal p value using Benjamini-Hochberg method47. Data were displayed using GENE-E software (http://www.broadinstitute.org/cancer/software/GENE-E).
In silico analysis of transcription factors binding to L1.
Transcription factor profiles were created using ChIP-seq data from the ENCODE project (GEO accession numbers GSE2961 and GSE32465). Transcription factor ChIP-seq and input control reads were aligned to the consensus sequence of L1HS using bowtie148. The log2 fold change enrichment was calculated per base pair of the L1HS consensus using the transcription factor ChIP-seq read coverage per million mapping reads (RPM) versus input control RPM values, and smoothed by LOESS smoothing with a parameter α=0.1. The total number of mapping reads used in RPM normalization was determined from a separate bowtie1 alignment to the human genome (hg19).
Construction of FOXA1 reporters.
L1 promoter reporter plasmids L1WT and L1 del (390–526) were obtained from Sergey Dmitriev, Institute of Bioorganic Chemistry, Moscow49,50. Both contain luciferase as the reporter cloned in the sense orientation. To determine antisense transcription from the same plasmid EYFP was inserted in the inverse orientation upstream of the L1 5’ UTR as follows. The EYFP sequence was excised from pEYFP-N1 (Clontech, Cat. # 6006–1) with AgeI and NotI and blunt ended. Plasmids L1WT and L1del were digested with XbaI, blunted and treated with FastAP (Fermentas). Successful insertion of anti-sense EYFP was verified using PCR primers AAAGTTTCTTATGGCCGGGC (in EYFP) and GCTGAACTTGTGGCCGTTTA (in L1 promoter) and Sanger sequencing. Plasmid pcDNA3.1/LacZ was used as the co-transfection control. Luciferase and β-galactosidase assays were performed as described49. EYFP-N1 was used as a positive control for detecting the EYFP signal. Co-transfections were performed on early passage LF1 cells using Lipofectamine with Plus Reagent (Invitrogen) according to the manufacturer’s instructions.
Lentiviral vectors.
Constructs were obtained from public depositories as indicated below. Virions were produced and target cells were infected as described (https://www.addgene.org/tools/protocols/plko/). shRNA sequences were obtained from The RNAi Consortium (TRC, http://www.broad.mit.edu/genome_bio/trc/rnai.html), cloned into third generation pLKO.1 vectors and tested for efficacy. Four selectable markers were used to allow multiple drug selections: pLKO.1 puro (2 μg/ml) and pLKO.1 hygro (200 μg/ml) (gifts from Bob Weinberg, Addgene plasmid # 8453, 24150), pLKO.1 blast (5 μg/ml) (gift from Keith Mostov, Addgene plasmid # 26655), pLKO.1 neo (250 μg/ml) (gift from Sheila Stewart, Addgene plasmid 13425). pLKO-RB1-shRNA63 and pLKO-RB1-shRNA19 were a gift from Todd Waldman (Addgene plasmids # 25641 and 25640)51. For FOXA1 shRNAs TRCN0000014881 (a) and TRCN0000014882 (b) were used. For TREX1 shRNAs TRCN0000007902 (a) and TRCN0000011206 (b) were used. For knockdown of L1 we designed and tested 9 shRNAs, of which two (shL1_11 to ORF1, AAGACACATGCACACGTATGT, and shL1_44 to ORF2 AAGACACATGCACACGTATGT) showed significant knockdown (Extended Data Fig. 5g) and were chosen for further work. The remaining 7 shRNAs produced no or minimal knockdown. For cGAS shRNAs TRCN0000128706 (a) and TRCN0000128310 (b) were used. For STING shRNAs TRCN0000161345 (a) and TRCN0000135555 (b) were used.
All ectopic expression experiments used constructs generated by the ORFeome Collaboration (http://www.orfeomecollaboration.org/) in the lentivirus vector pLX304 (blasticidin resistant, Addgene plasmid 25890) and were obtained from the DNASU plasmid repository (https://dnasu.org/DNASU/Home.do): RB1 (ccsbBroad304_06846, HsCD00434323), TREX1 (ccsbBroad304_02667, HsCD00445909), FOXA1 (ccsbBroad304_06385, HsCD00441689).
All the interventions in senescent cells were initiated by infecting cells at 12 weeks of senescence (point D in Extended Data Fig. 1a). Following appropriate drug selections cells were incubated until 16 weeks of senescence (point E in Extended Data Fig. 1a), when they were harvested for further analysis.
The 3X intervention was performed by infecting early passage LF1 cells sequentially with vectors pLKO.1 puro shRB, pLKO.1 hygro shTREX1 and pLX304 blast FOXA1 (Extended Data Fig. 5c). After each infection the arising drug resistant pool of cells was immediately infected with the next vector. After the third infection the cells were harvested for further analysis 48 hours after the drug selection was complete. The infections were also performed in various combinations and in each case resulted in the activation of L1 expression, entry into senescence, and induction of an IFN-I response. The sequence above was chosen because it gave the most efficient selection of cells for further analysis. To allow an additional (fourth) intervention in 3X cells (shL1, shSTING, or shCGAS), hairpins targeting RB1 were re-cloned in pLKO.1 neo, thus freeing pLKO.1 puro for the fourth gene of interest. This allowed an efficient drug selection process and sample harvest 48 hrs. after the last selection.
Retrotransposition reporters.
The two-vector dual luciferase reporter system reported by Xie et al. (2011)52 was adapted for lentiviral delivery. The L1RP-Fluc reporters were recloned from plasmids pWA355 and pWA366 into the lentiviral backbone pLX304. pWA355 contains a functional, active L1RP element, whereas pWA366 contains L1RP(JM111), a mutated element carrying two missense mutations in ORF1 that is unable to retrotranspose. Early passage LF1 cells were infected with a puromycin resistant lentivirus expressing Rluc. Pooled drug resistant cells were then infected with high titer particles of pLX304-WA355 or pLX304-WA366 constructs. Immediately after infection cells were treated for four days with 3TC (at the indicated concentrations). Cells were then harvested and assayed for Rluc amd Fluc luciferase activities. The native L1 retrotransposition reporter pLD14353 was co-transfected with pLKO vectors (shLuc, shL1_11 and shL1_44) into HeLa cells using FuGene HD (Promega). Cell culture, transfection and retrotransposition assays were done as described above. Retrotransposition activity was normalized to the activity of L1RP co-transfected with shLuc. Three independent experiments were performed for each construct.
Identification of expressed L1 elements by long-range RT-PCR and 5’RACE.
Total RNA was harvested from cells using the Trizol reagent (Invitrogen). The RNA was further purified using the Purelink RNA Mini kit (Invitrogen) with DNase I digestion. From the eluted total RNA, poly(A) RNA was isolated using the NEBNext Poly(A) mRNA Magnetic Isolation Module (New England Biolabs). The forward primer (MDL15UTRPRAF, primer set 1, Supplementary Table 1) was used with either of two reverse primers (MDL15UTRPRCR, primer set 3, amplicon size 537 bp) or MDL15UTRPRDR, primer set 4, amplicon size 654 bp). A high-fidelity thermostable reverse transcriptase (PyroScript RT-PCR Master Mix Kit, Lucigen) was used with 10 ng of poly(A) mRNA per reaction and amplified for 10 cycles. No template and RNaseA treated samples were used as negative controls. The generated amplicons were cloned into the TOPO-TA (Invitrogen) vector and the resulting plasmids were used to transform One Shot TOP10 chemically competent E. coli. Individual colonies were picked and subjected to Sanger sequencing using a T7 promoter sequencing primer at Beckman Coulter Genomics. 96 sequencing reactions (1 plate) were performed for each primer pair in four experiments for a total of 768 sequenced clones. Sequencing data were trimmed to remove the RT-PCR primers and BLASTed against the human genome (GRCh38) with a match/mismatch cost of +1, −4 and allowing species-specific repeats for Homo sapiens. Only perfect hits were scored and annotated for genomic coordinates. 658 clones could be mapped to the reference genome, 51 contained at least 1 mismatch and thus likely represent elements that are polymorphic in the cell line, and 58 were cloning artifacts. Whenever a clone presented multiple instances of perfect identity a fractional count was adopted, dividing the counts by the number of elements sharing the same sequence. Each mappable clone was further analyzed using L1Xplorer54 to recover the classification features of the L1 element and whether it is intact.
Alternatively, poly(A) RNA isolated as above was subjected to Rapid Amplification of cDNA Ends (RACE). Each reaction contained 10 ng of poly(A) RNA and was processed using the 5’RACE System kit (Thermo Fisher, Cat. # 18374–041). The two antisense gene-specific primers (GSP) used for 5’RACE were: for GSP1, MDL15UTRPRDR (primer set 4, Supplementary Table 1), and for the nested GSP2, MDL15UTRPRCR (primer set 3, Supplementary Table 1). Amplification products were cloned and sequenced as above, using a T7 promoter sequencing primer by Beckman Coulter Genomics. A total of 94 clones were sequenced; 26 contained mostly a polyG stretch generated by the tailing step in the RACE protocol and 18 could not be mapped to the human genome. The remaining 50 mappable clones contained L1 sequences and were aligned to the L1HS consensus using a setting of >95% identity at positions 1–450 (http://www.girinst.org/repbase/update/browse.php). The mappable clones were also assigned to individual L1 families using RepEnrich software55. Pairwise alignments to the consensus were performed with LALIGN56. Multiple sequence alignments were calculated using MAFFT (Multiple Alignment using Fast Fourier Transform) with the L-INS-i algorithm (accurate for alignments of <200 sequences)57. Alignment visualization, %-identity coloring and consensus were generated by Jalview58.
Generation and analysis of CRISPR-Cas9 knockouts.
Three distinct gRNA sequences for each chain of the IFNAR receptor (IFNAR1 and IFNAR2), listed in the GeCKO v2.0 resource (Feng Zhang Lab, MIT, http://genome-engineering.org/gecko/?page_id=15)59, were tested and the following ones were chosen: IFNAR1 (HGLibA_29983) AACAGGAGCGATGAGTCTGTA; IFNAR2 (HGLibA_29985) GTGTATATCAGCCTCGTGTT. Cas9 and gRNAs were delivered using a single lentivirus vector (LentiCRISPR_v2, Feng Zhang Lab, MIT; Addgene plasmid # 52961), carrying a puromycin resistance gene. The efficacy of the CRISPR-Cas9 mutagenesis, on the basis of which the above two gRNAs were chosen, was evaluated by treating the infected and drug-selected cells with interferon (universal type I interferon, PBL Assay Science, Cat. # 11200–1) and monitoring nuclear translocation of phospho-STAT2 and IRF9 by immunofluorescence. The absence of translocation signifies lack of IFN-I responsiveness and hence loss of IFNAR function. Experimental procedures followed the protocols provided by the Zhang lab (http://genome-engineering.org/gecko/wp-content/uploads/2013/12/lentiCRISPRv2-and-lentiGuide-oligo-cloning-protocol.pdf)60. In the experiment shown in Fig. 3h (RS) and Extended Data Fig. 5k, both IFNAR1 and IFNAR2 gRNAs were used to treat the same cells to further increase the efficacy of ablating the INF-I response. For early passage and senescent cells co-infections of IFNAR1 and IFNAR2 vectors were performed followed by selection with puromycin. For senescent cells high titer lentivirus particles were applied to senescent cells at 12 weeks in senescence (point D, Extended Data Fig. 1a) and cells were assayed 4 weeks later (point E, Extended Data Fig. 1a). For the experiment shown in Fig. 3h (SIPS), edited early passage cells were single-cell cloned. 24 single cells were isolated using the CellRaft technology (Cell Microsystems) and expanded. Genomic screening of the CRISPR cut site was performed by the CRISPR Sequencing Service (CCIB DNA Core, Massachusetts General Hospital, https://dnacore.mgh.harvard.edu/). The successful knock out of IFNAR1 and IFNAR2 was verified in 4 out of the 24 expanded clonal cell lines.
Immunoblotting.
Cells were harvested in Laemmli sample buffer (60 mM Tris pH 6.8, 2% SDS, 10% glycerol, 100 mM DTT) and boiled for 5 min. at 100°C. Whole cell extracts (60 μg protein) were separated by SDS-PAGE and transferred onto Immobilon-FL membranes (Millipore). Nonspecific binding was blocked by incubation in 4% bovine serum albumin (BSA; Thermo Fisher) and 0.1% Tween-20 in PBS for 1 hr. at room temperature. Primary antibodies were diluted in the blocking solution and incubated overnight at 4°C. A list of all the primary antibodies is provided in Supplementary Table 2. Secondary antibodies were diluted in blocking solution and incubated for 1 hr. at room temperature. Signals were detected using the LI-COR Odyssey infrared imaging system (LI-COR Biosciences). For the quantification of signals all samples to be compared were run on the same gel. Loading standards were visualized on the same blot as the test samples using the LI-COR 2-color system. Bands were imaged and quantified using LI-COR software. All bands to be compared were quantified on the same image and were within the linear range of detection of the instrument.
Immunofluorescence microscopy performed on cells in culture.
Cells were grown on glass cover slips and the samples were processed as previously described61. Primary antibodies are listed in Supplementary Table 2. Staining of ssDNA was performed as described by Thomas et al11. Briefly, cells seeded on coverslips were fixed on ice with 4% paraformaldehyde (PFA) for 20 min. and then incubated in 100% methanol at −20°C overnight. The cells were then treated with 200 mg/mL RNase A at 37°C for 4 hrs. Cells were blocked with 3% BSA and incubated overnight at 4°C with primary antibodies diluted in 3% BSA. Images were acquired using a Zeiss LSM 710 confocal laser scanning microscope or a Nikon Ti-S inverted fluorescence microscope. All microscope settings were set to collect images below saturation and were kept constant for all images taken in one experiment, as previously described61. Image analysis was performed as described below for tissues.
PCR arrays.
Total RNA was harvested from cells as indicated above (Quantitative PCR) and analyzed using the Qiagen RT² Profiler™ Human Type I Interferon Response PCR Array (Cat. # PAHS-016ZE-4). Reverse transcription reactions were performed with the Qiagen RT2 First Strand Kit (Cat. # 330404) using 1μg of total RNA as starting material. 102 μl of the completed reaction was combined with 650 μl of Qiagen RT² SYBR Green ROX qPCR Mastermix (Cat. # 330521) and 548 μl of RNase-free molecular grade water, and run in the 384-well block on a ViiA 7 Applied Biosystems instrument. All procedures followed the manufacturer’s protocols. All conditions were run in triplicate. The results were analyzed using the Qiagen GeneGlobe Data Analysis Center (http://www.qiagen.com/us/shop/genes-and-pathways/data-analysis-center-overview-page/). Briefly, Ct values were normalized to a panel of house keeping genes (HKG). ΔCt values ware calculated between a gene of interest (GOI) and the mean HKG value. Fold changes were then calculated using 2^ (-ΔΔCT) formula. The lower limit of detection was set at Ct of 35. For any GOI to be considered significant the following filters were set: 1) >2-fold change in expression; 2) p-value >0.05. In addition, genes with an average Ct > 32 in both control and test samples were also eliminated.
Enzyme Linked Immunosorbent Assay (ELISA).
Interferon β levels were quantified with the VeriKine-HS Human IFN Beta Serum ELISA Kit (PBL Assay Science, Cat. # 41415). Cell culture media were conditioned for 48 hrs. before harvest. To remove particles and debris, 1 ml aliquots were spun 5 minutes 5,000 x g. All incubations were performed in a closed chamber at room temperature (22–25ºC) keeping the plate away from temperature fluctuations. 50 μl of sample buffer followed by 50 μl of diluted antibody solution were added to each well. Finally, 50 μl of test samples, standards or blanks were added per well. Plates were sealed and shaken at 450 rpm for 2 hrs. At the end of the incubation period the contents of the plate were removed and the wells were washed three times with 300 μl of diluted wash solution. 100 μl of HRP solution was added to each well and incubated for 30 min. under constant shaking. The wells were emptied and washed four times with wash solution. 100 μl of the TMB substrate solution was added to each well. Plates were incubated in the dark for 30 min. Finally, 100 μl of stop solution was added to each well and within 5 min. absorbance at 450 nm was recorded. The values recorded for the blank controls were subtracted from the standards as well as sample values to eliminate background. Optical densities (OD) units were plotted using a 4-parameter fit for the standard curve and were used to calculate the interferon titers in the samples.
Human tissue specimens.
We are grateful to Andrea Maier, Mariette Waaijer and Rudi Westendorp for assistance with the human specimens. Human skin specimens were collected as part of the Leiden Longevity Study62,63 and were provided by P. Eline Slagboom, Leiden University Medical Centre, Netherlands. Informed consent was obtained and all protocols were approved by the ethical committee of the Leiden University Medical Centre. The samples were collected as 4 mm thickness full depth punch biopsies, embedded in optimal cutting compound (OCT), flash frozen, and stored at −80°C. Samples were shipped on dry ice to Brown University. The Brown investigators were blinded to everything except the age and sex of the subjects. The OCT-embedded specimens were cryosectioned at 8 μm thickness using a Leica CM3050S cryomicrotome. The slides were fixed with 4% PFA and 0.5% Triton X-100 in PBS (prewarmed to 37 °C) for 20 min. at room temperature. No further permeabilization was performed. Antibody incubation was preceded by a blocking step with 4% bovine serum albumin (BSA; fraction V, Thermo Fisher), 2% donkey serum, 2% rabbit serum and 0.1% Triton X-100 in PBS for 1 hr. at room temperature. Primary antibodies were diluted in the above blocking solution (1:200) and incubated overnight at 4 °C with rocking in a humidified chamber. The secondary antibodies (AlexaFluor 546 and AlexaFluor 647, Life Technologies) were also diluted in blocking solution and incubated for 2 hrs. at room temperature. Three 15 min. washing steps in PBS, containing 0.2% Triton X-100, followed each antibody incubation. Nuclei were counterstained with 2 μg/ml DAPI in PBS, containing 0.2% Triton X-100, for 15 min. Stained slides were mounted with ProLong Antifade Mountant without DAPI (Life Technologies) and imaged on a Zeiss LSM 710 Confocal Laser Scanning Microscope. A z-series encompassing the full thickness of the tissue was collected for each field. All microscope settings and exposure times were set to collect images below saturation and were kept constant for all images taken in one experiment. Image analysis was performed using either CellProfiler software64, or ImageJ open source software from the NIH (http://rsbweb.nih.gov/ij/). Nuclei were defined using the DAPI channel. Cell outlines were defined by radially expanding the nuclear mask using the function Propagate until an intensity threshold in the AlexaFluor 546 and AlexaFluor 647 channels was reached. The fluorescence intensity within these regions was then recorded in both channels. For each sample a total of 200 nuclei were recorded in multiple fields. Mouse tissue sections were processed and analyzed in the same way as described above.
Mouse tissue specimens.
Total RNA was extracted from 50 mg of visceral adipose, small intestine, skeletal muscle, brown adipose or liver tissue by mincing followed by homogenization in Trizol (Invitrogen) using a Power Gen 125 homogenizer (Fischer Scientific). After phase separation, the RNA in the aqueous layer was purified using the Purelink RNA Mini kit (Invitrogen) with DNase I digestion. To assess gene expression by RT-qPCR 1 μg of total RNA was reverse transcribed as described above. In each individual experiment all samples were processed in parallel and no blinding was introduced.
Imaging of whole-mount white adipose tissue followed the method described by Martinez-Santibañez et al. (2014)65. Briefly, white adipose tissue (visceral depot) were subdivided into 0.5–1 cm3 sized pieces and incubated in 10 ml of fresh fixing buffer (1% PFA in PBS pH 7.4) for 30 min. at room temperature with gentle rocking. After three washing steps with PBS, the tissue blocks were cut in six equal pieces. All subsequent incubations were performed in 2 ml cylindrical microcentrifuge tubes. Primary antibody incubation was preceded by a blocking step with 5% BSA, 0.1% Saponin in PBS for 30 min. at room temperature. Primary antibodies were diluted in the above blocking solution (1:200) and incubated overnight at 4 °C with gentle rocking. The secondary antibodies (AlexaFluor 546, AlexaFluor 594 and AlexaFluor 647, Life Technologies) were also diluted in blocking solution and incubated for 2 hrs. at room temperature. Three 10 min. washing steps in PBS followed each antibody incubation. Antibody-independent staining of nuclei and lipids was performed after immuno-staining: DAPI and BODIPY (Thermo Fisher) were diluted in PBS with 5% BSA and incubated with tissue specimens for 20 min. followed by three washing steps as above. Stained samples were carefully placed on confocal-imaging optimized #1.5 borosilicate glass chamber slides. A small drop of PBS prevented drying. Acquired images were analyzed as described above.
Co-staining of SA-β-Gal activity and ORF1 protein in liver sections was performed by staining for SA-β-Gal first as described66. Subsequently, samples underwent heat-induced epitope retrieval by steaming for 20 min. in antigen retrieval buffer (10 mM Tris, 1 mM EDTA, 0.05% Tween 20, pH 9.0). Samples were then processed for immunofluorescence staining as above (Human tissue specimens).
Kidney tissue preserved in OCT was cryosectioned, treated for 10 min. with 0.5% (w/v) periodic acid, then stained with periodic acid-Schiff’s (PAS) reagent (Fisher Scientific, Cat. #SS32–500) for 10 min. Stained tissue sections were mounted with Shandon Aqua Mount (Fisher Scientific, Cat. #14–390-5) and then imaged under bright field illumination. Glomerulosclerosis was scored as described26. Briefly, 40 glomeruli per animal were assessed in a blinded fashion and assigned scores of 1–4: score of 1, <25% sclerosis; 2, 25–50% sclerosis; 3, 50–75% sclerosis; 4, >75% sclerosis. The feature used to assess sclerosis was the strength and pervasiveness of PAS-positive lesions within the glomeruli. As exemplified in Fig. 4e, a sclerotic glomerulus is more shrunken and stains more intensely with PAS.
We thank Darren Baker for guidance with the glomerulosclerosis assay.
Quadriceps muscles were embedded in OCT, sectioned at 12 μm thickness and mounted onto positively charged slides. Sections were stained with H&E (hematoxylin, 3 min. followed by 30 eosin, sec.). Mounted slides were imaged on a Zeiss Axiovert 200M microscope equipped with a Zeiss MRC5 color camera. To measure muscle fiber diameter, the shortest distance across ~100 muscle fibers per animal was measured using ImageJ software as described27. The Kolmogorov-Smirnov test was used to assess the statistical significance of the difference between the resulting distributions.
Statistical treatments.
Excel was used to perform general statistical analyses (means, s.d., t-tests, etc). R software for statistical computing (64-bit version 3.3.2) was used for 1-way ANOVA and Tukey’s multiple comparisons post-hoc test. For consistency of comparisons significance in all figures is denoted as follows: *P < 0.05, **P < 0.01. Sample sizes were based on previously published experiments and previous experience in which differences were observed. No statistical test was used to pre-determine sample size. No samples were excluded. All attempts at replication were successful. There were no findings that were not replicated or could not be reproduced. The nature and numbers of samples analyzed (defined as n) in each experiment are listed in the figure legends. The number of independent experiments is also listed in figure legends. The investigators were blinded when quantifying immunofluorescence results. Fields or sections of tissues for quantification were randomly selected and the scored, using methods as indicated for individual experiments. The investigators were also blinded when scoring glomerulosclerosis and muscle fiber diameter. For RNA-seq and PCR array experiments the statistical treatments are described under those sections (above).
Extended Data
Supplementary Material
Acknowledgments.
The following funding sources are acknowledged: M.D., Glenn/AFAR Postdoctoral Fellowship, NIH P20 GM119943 COBRE pilot award; T.I., NIH F31 AG043189; A.P.P. and A.E.E., NIH T32 AG041688; S.W.C., NIH F31 AG050365; A.C. and G.B., Biotechnology and Sport Medicine Fellowships, School of Pharmacy, University of Bologna, Bologna, Italy; E.M.A, and J.D.B., NIH P01 AG051449; C.B., Canadian Institute of Health Research MOP-102709; J.A., NIH DP1 GM114862, R01 EY022238, R01 EY024068, R01 EY028027, John Templeton Foundation Grant ID 60763; M.S., A.S. and V.G., NIH R01 AG046320, R01 AG027237, R01 AG047200, P01 AG051449, Life Extension Foundation; S.L.H., NIH R37 AG016667, R01 AG024353, P01 AG051449, Glenn-AFAR Breakthroughs in Gerontology Award; N.N., NIH R01 AG050582, P20 GM109035; J.M.S., NIH R37 AG016694, P01 AG051449. We are grateful to Andrea Maier, Mariette Waaijer, Rudi Westendorp and the participants of the Leiden Longevity Study (LLS) for assistance with the human specimens. The biomaterials collection of the LLS (P. Eline Slagboom, principal investigator) was supported by the Netherlands Genomics Initiative of the Netherlands Organization for Scientific Research (NWO), within the framework of the Netherlands Consortium of Healthy Ageing (NCHA, 050–060-810) and the Leiden University Medical Center.
Footnotes
Competing Financial Interests. J.A. is a cofounder of iVeena Holdings, iVeena Delivery Systems, and Inflammasome Therapeutics, and has been a consultant for Allergan, Biogen, Boehringer-Ingelheim, Janssen, Olix Pharmaceuticals, and Saksin LifeSciences in a capacity unrelated to this work. J.A. and K.A. are named as inventors on patent applications on macular degeneration filed by the University of Kentucky or the University of Virginia. J.D.B is a founder and Director of Neochromosome, Inc., the Center of Excellence for Engineering Biology, and CDI Labs, Inc. He serves on the Scientific Advisory Boards of Modern Meadow, Inc., Recombinetics, Inc., and Sample6, Inc.
Data availability. All source data and exact P values (if applicable) for every figure are included in the supporting information that accompanies the paper. RNA-seq data are on the Gene Expression Omnibus (GEO) with accession number GSE109700. Any other data or information relevant to this study are available from the corresponding author upon reasonable request.
References
- 1.Huang CR, Burns KH & Boeke JD Active transposition in genomes. Annu. Rev. Genet. 46, 651–75 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.de Koning AP et al. Repetitive elements may comprise over two-thirds of the human genome. PLoS Genet. 7, e1002384 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Hancks DC & Kazazian HH Jr Active human retrotransposons: variation and disease. Curr. Opin. Genet. Dev. 22, 191–203 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Rodic N et al. Long interspersed element-1 protein expression is a hallmark of many human cancers. Am. J. Pathol. 184, 1280–6 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Erwin JA, Marchetto MC & Gage FH Mobile DNA elements in the generation of diversity and complexity in the brain. Nat. Rev. Neurosci. 15, 497–506 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.De Cecco M et al. Genomes of replicatively senescent cells undergo global epigenetic changes leading to gene silencing and activation of transposable elements. Aging Cell 12, 247–256 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Van Meter M et al. SIRT6 represses LINE1 retrotransposons by ribosylating KAP1 but this repression fails with stress and age. Nat Commun 5, 5011 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Kreiling JA et al. Contribution of retrotransposable elements to aging in Human Retrotransposons in Health and Disease (ed. Cristofari G) 297–321 (Springer International, 2017). [Google Scholar]
- 9.Volkman HE & Stetson DB The enemy within: endogenous retroelements and autoimmune disease. Nat. Immunol. 15, 415–22 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Salama R, Sadaie M, Hoare M & Narita M Cellular senescence and its effector programs. Genes Dev 28, 99–114 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Thomas CA et al. Modeling of TREX1-dependent autoimmune disease using human stem cells highlights L1 accumulation as a source of neuroinflammation. Cell Stem Cell 21, 319–331 e8 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Ishak CA et al. An RB-EZH2 complex mediates silencing of repetitive DNA sequences. Mol Cell 64, 1074–1087 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Li Q et al. FOXA1 mediates p16(INK4a) activation during cellular senescence. EMBO J. 32, 858–73 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Denli AM et al. Primate-specific ORF0 contributes to retrotransposon-mediated diversity. Cell 163, 583–93 (2015). [DOI] [PubMed] [Google Scholar]
- 15.Dai L, Huang Q & Boeke JD Effect of reverse transcriptase inhibitors on LINE-1 and Ty1 reverse transcriptase activities and on LINE-1 retrotransposition. BMC Biochem. 12, 18 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Coufal NG et al. L1 retrotransposition in human neural progenitor cells. Nature 460, 1127–31 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Dhanwani R, Takahashi M & Sharma S Cytosolic sensing of immuno-stimulatory DNA, the enemy within. Curr Opin Immunol 50, 82–87 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Fowler BJ et al. Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity. Science 346, 1000–3 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Herbig U et al. Cellular senescence in aging primates. Science 311, 1257 (2006). [DOI] [PubMed] [Google Scholar]
- 20.Coppe JP, Desprez PY, Krtolica A & Campisi J The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5, 99–118 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Chang J et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med 22, 78–83 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Zhu Y et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14, 644–58 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Tchkonia T et al. Fat tissue, aging, and cellular senescence. Aging Cell 9, 667–84 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Mattson MP Perspective: Does brown fat protect against diseases of aging? Ageing Res Rev 9, 69–76 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Frasca D & Blomberg BB Inflammaging decreases adaptive and innate immune responses in mice and humans. Biogerontology 17, 7–19 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Baker DJ et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature 530, 184–9 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Baker DJ et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 479, 232–6 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.West AP & Shadel GS Mitochondrial DNA in innate immune responses and inflammatory pathology. Nat Rev Immunol 17, 363–375 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Dou Z et al. Cytoplasmic chromatin triggers inflammation in senescence and cancer. Nature 550, 402–406 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Takahashi A et al. Downregulation of cytoplasmic DNases is implicated in cytoplasmic DNA accumulation and SASP in senescent cells. Nat Commun 9, 1249 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Franceschi C & Campisi J Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J. Gerontol. A Biol. Sci. Med. Sci. 69 Suppl 1, S4–9 (2014). [DOI] [PubMed] [Google Scholar]
- 32.Lopez-Otin C et al. The hallmarks of aging. Cell 153, 1194–217 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Brown JP, Wei W & Sedivy JM Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 277, 831–4 (1997). [DOI] [PubMed] [Google Scholar]
- 34.Herbig U et al. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol. Cell 14, 501–13 (2004). [DOI] [PubMed] [Google Scholar]
- 35.Fumagalli M, Rossiello F, Mondello C & d’Adda di Fagagna F Stable cellular senescence is associated with persistent DDR activation. PLoS One 9, e110969 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Ambati J, Fowler B & Ambati K Compositions and Methods for Treating Retinal Degradation. in PCT Patent Publication WO/2016/138425 (2016).
- 37.Else LJ et al. Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrob. Agents Chemother. 56, 1427–33 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Le ON et al. Ionizing radiation-induced long-term expression of senescence markers in mice is independent of p53 and immune status. Aging Cell 9, 398–409 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Li W et al. The EMBL-EBI bioinformatics web and programmatic tools framework. Nucleic Acids Res. 43, W580–4 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Ye J et al. Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinf. 13, 134 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Gautier G et al. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J. Exp. Med. 201, 1435–46 (2005). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Kim D, Langmead B & Salzberg SL HISAT: a fast spliced aligner with low memory requirements. Nat Methods 12, 357–60 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Liao Y, Smyth GK & Shi W featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–30 (2014). [DOI] [PubMed] [Google Scholar]
- 44.Robinson MD, McCarthy DJ & Smyth GK edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Reich M et al. GenePattern 2.0. Nat Genet 38, 500–1 (2006). [DOI] [PubMed] [Google Scholar]
- 46.Subramanian A et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102, 15545–50 (2005). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Benjamini Y & Hochberg Y Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc B 57, 289–300 (1995). [Google Scholar]
- 48.Langmead B Aligning short sequencing reads with Bowtie. Curr. Protoc. Bioinformatics Chapter 11, Unit 11.7 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Alexandrova EA et al. Sense transcripts originated from an internal part of the human retrotransposon LINE-1 5’ UTR. Gene 511, 46–53 (2012). [DOI] [PubMed] [Google Scholar]
- 50.Olovnikov IA et al. A key role of the internal region of the 5’-untranslated region in the human L1 retrotransposon transcription activity. Mol. Biol. (Mosk) 41, 508–14 (2007). [PubMed] [Google Scholar]
- 51.Michaud K et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res. 70, 3228–38 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Xie Y et al. Characterization of L1 retrotransposition with high-throughput dual-luciferase assays. Nucleic Acids Res 39, e16 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.An W et al. Characterization of a synthetic human LINE-1 retrotransposon ORFeus-Hs. Mob DNA 2, 2 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Penzkofer T, Dandekar T & Zemojtel T L1Base: from functional annotation to prediction of active LINE-1 elements. Nucleic Acids Res 33, D498–500 (2005). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Criscione SW et al. Transcriptional landscape of repetitive elements in normal and cancer human cells. BMC Genomics 15, 583 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Childs BG, Durik M, Baker DJ & van Deursen JM Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat. Med. 21, 1424–35 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Katoh K & Standley DM MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol 30, 772–80 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Waterhouse AM et al. Jalview Version 2--a multiple sequence alignment editor and analysis workbench. Bioinformatics 25, 1189–91 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Sanjana NE, Shalem O & Zhang F Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783–4 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Shalem O et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84–7 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Kreiling JA et al. Age-associated increase in heterochromatic marks in murine and primate tissues. Aging Cell 10, 292–304 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Schoenmaker M et al. Evidence of genetic enrichment for exceptional survival using a family approach: the Leiden Longevity Study. Eur. J. Hum. Genet. 14, 79–84 (2006). [DOI] [PubMed] [Google Scholar]
- 63.Waaijer ME et al. The number of p16INK4a positive cells in human skin reflects biological age. Aging Cell 11, 722–5 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Kamentsky L et al. Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis software. Bioinformatics 27, 1179–80 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Martinez-Santibanez G, Cho KW & Lumeng CN Imaging white adipose tissue with confocal microscopy. Methods Enzymol 537, 17–30 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Itahana K, Campisi J & Dimri GP Methods to detect biomarkers of cellular senescence: the senescence-associated beta-galactosidase assay. Methods Mol. Biol. 371, 21–31 (2007). [DOI] [PubMed] [Google Scholar]
- 67.Schorl C & Sedivy JM Analysis of cell cycle phases and progression in cultured mammalian cells. Methods 41, 143–50 (2007). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Rangwala SH, Zhang L & Kazazian HH Jr. Many LINE1 elements contribute to the transcriptome of human somatic cells. Genome Biol 10, R100 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Athanikar JN, Badge RM & Moran JV A YY1-binding site is required for accurate human LINE-1 transcription initiation. Nucleic Acids Res. 32, 3846–55 (2004). [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.